Single-center comparison of three chemoembolization regimens for hepatocellular carcinoma

Journal of Vascular and Interventional Radiology

Volumn 24, Issue 2, 2013, Pages 266-273

  Petruzzi, Nicholas J ^a   Frangos, Andrea J ^a   Fenkel, Jonathan M ^a   Herrine, Steven K ^a   Hann, Hie Won ^a   Rossi, Simona ^a   Rosato, Ernest L ^a   Eschelman, David J ^a   Gonsalves, Carin F ^a   Brown, Daniel B ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CISPLATIN; DOXORUBICIN; ETHIODIZED OIL; MITOMYCIN; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CANCER GROWTH; CHEMOEMBOLIZATION; CHILD PUGH SCORE; COMPARATIVE STUDY; DEATH; ENDOSCOPIC THERAPY; FEMALE; HEMATEMESIS; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; SKIN MANIFESTATION; STOMACH ULCER; TUMOR RUPTURE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CISPLATIN; DOXORUBICIN; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; PENNSYLVANIA; PREVALENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84873103303     PISSN: 10510443     EISSN: 15357732     Source Type: Journal    
DOI: 10.1016/j.jvir.2012.10.025     Document Type: Article

References (42)

1. J.M. Llovet, M.I. Real, and X. Montana Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 2002 1734 1739
2. C.M. Lo, H. Ngan, and W.K. Tso Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 35 2002 1164 1171
3. D.B. Brown, J.F. Geschwind, M.C. Soulen, S.F. Millward, and D. Sacks Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies J Vasc Interv Radiol 20 suppl 2009 S317 S323
4. J. Bruix, and M. Sherman Management of hepatocellular carcinoma Hepatology 42 2005 1208 1236
5. T. Decaens, F. Roudot-Thoraval, and S. Hadni-Bresson Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time Liver Transpl 12 2006 1761 1769
6. V. Mazzaferro, E. Regalia, and R. Doci Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis N Engl J Med 334 1996 693 699
7. A. Bharat, D.B. Brown, and J.S. Crippin Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival J Am Coll Surg 203 2006 411 420
8. W.C. Chapman, M.B. Majella Doyle, and J.E. Stuart Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation Ann Surg 248 2008 617 625
9. J. Bruix, M. Sherman, and J.M. Llovet Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430
10. D.L. Reidy, and J.D. Schwartz Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials - I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma Anticancer Drugs 15 2004 427 437
11. R. Sacco, I. Bargellini, and M. Bertini Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma J Vasc Interv Radiol 22 2011 1545 1552
12. B. Solomon, M.C. Soulen, R.A. Baum, Z.J. Haskal, R.D. Shlansky-Goldberg, and C. Cope Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U.S. population J Vasc Interv Radiol 10 1999 793 798
13. D.B. Brown, W.C. Chapman, and R.D. Cook Chemoembolization of hepatocellular carcinoma: patient status at presentation and outcome over 15 years at a single center AJR Am J Roentgenol 190 2008 608 615
14. M. Buijs, J.A. Vossen, and C. Frangakis Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization - single-center experience Radiology 249 2008 346 354
15. J. Lammer, K. Malagari, and T. Vogl Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study Cardiovasc Intervent Radiol 33 2010 41 52
16. K. Malagari, M. Pomoni, and T.N. Spyridopoulos Safety profile of sequential transcatheter chemoembolization with DC Bead: results of 237 hepatocellular carcinoma (HCC) patients Cardiovasc Intervent Radiol 34 2011 774 785
17. R. Gillmore, S. Stuart, and A. Kirkwood EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization J Hepatol 55 2011 1309 1316
18. K. Memon, L. Kulik, and R.J. Lewandowski Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times Gastroenterology 141 2011 526 535
19. J.H. Shim, H.C. Lee, and S.O. Kim Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models Radiology 262 2012 708 718
20. C. Frangakis, J.F. Geschwind, and D. Kim Chemoembolization decreases drop-off risk of hepatocellular carcinoma patients on the liver transplant list Cardiovasc Intervent Radiol 34 2011 1254 1261
21. K. Memon, L. Kulik, and R.J. Lewandowski Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: A subgroup analysis J Hepatol 56 2012 1112 1120
22. D.B. Brown, B. Nikolic, and A.M. Covey Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy J Vasc Interv Radiol 23 2012 287 294
23. R.J. Lewandowski, D. Wang, and J. Gehl A comparison of chemoembolization endpoints using angiographic versus transcatheter intraarterial perfusion/MR imaging monitoring J Vasc Interv Radiol 18 2007 1249 1257
24. R. Lencioni, and J.M. Llovet Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 2010 52 60
25. J.M. Llovet, A.M. Di Bisceglie, and J. Bruix Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
26. A. Trotti, A.D. Colevas, and A. Setser CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 2003 176 181
27. C.S. Georgiades, E. Liapi, and C. Frangakis Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization J Vasc Interv Radiol 17 2006 1619 1624
28. H. Yodono, K. Matsuo, and A. Shinohara A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma Anticancer Drugs 22 2011 277 282
29. A. Grieco, M. Pompili, and G. Caminiti Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre Gut 54 2005 411 418
30. A. Guglielmi, A. Ruzzenente, and S. Pachera Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response Am J Gastroenterol 103 2008 597 604
31. M. Barone, G.C. Ettorre, and R. Ladisa Transcatheter arterial chemoembolization (TACE) in treatment of hepatocellular carcinoma Hepatogastroenterology 50 2003 183 187
32. D.B. Brown, T.K. Pilgram, and M.D. Darcy Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents J Vasc Interv Radiol 16 2005 1661 1666
33. H. Yeh, E. Smoot, D.A. Schoenfeld, and J.F. Markmann Geographic inequity in access to livers for transplantation Transplantation 91 2011 479 486
34. R.H. Wiesner, R.B. Freeman, and D.C. Mulligan Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy Gastroenterology 127 suppl 2004 S261 S267
35. R. Dhanasekaran, D.A. Kooby, C.A. Staley, J.S. Kauh, V. Khanna, and H.S. Kim Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocellular carcinoma (HCC) J Surg Oncol 101 2010 476 480
36. J. Iwazawa, S. Ohue, N. Hashimoto, and T. Mitani Local tumor progression following lipiodol-based targeted chemoembolization of hepatocellular carcinoma: a retrospective comparison of miriplatin and epirubicin Cancer Manag Res 4 2012 113 119
37. K. Kamada, T. Nakanishi, and M. Kitamoto Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion J Vasc Interv Radiol 12 2001 847 854
38. S. Kawai, M. Tani, and J. Okamura Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan Semin Oncol 24 suppl 1997 S6-38 S36-45
39. A. Nicolini, L. Martinetti, S. Crespi, M. Maggioni, and A. Sangiovanni Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma J Vasc Interv Radiol 21 2010 327 332
40. Sahara S, Kawai N, Sato M, et al. Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol (In press). DOI:10.1007/s00270-012-0352-x.
41. M.J. Song, C.H. Park, and J.D. Kim Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients Eur J Gastroenterol Hepatol 23 2011 521 527
42. R. Salem, R.J. Lewandowski, and L. Kulik Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma Gastroenterology 140 2011 497 507